World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya & Malawi that has reached more than 800 000 children since 2019.
The vaccine is developed by British drugmaker GlaxoSmithKline (GSK). Many vaccines exist against viruses and bacteria but this was the first time that the WHO recommended broad use of a vaccine against a human parasite. The vaccine acts against Plasmodium falciparum, one of five parasite species and the most deadly. The symptoms of malaria are fever, headaches, and muscle pain, then cycles of chills, fever, and sweating.
Important takeaways for all competitive exams:
India has many cities known for their unique identity, and some of them are famous…
Global credit rating agency Fitch Ratings has revised India’s GDP growth forecast for FY26 to…
In a landmark shift in Pakistan’s military command structure, Field Marshal Asim Munir has been…
India’s Smart Cities Mission (SCM), launched in 2015, is entering its final stretch with an…
Welcome to the November 2025 Edition of the Affairs PDF – your all-inclusive monthly guide to…
The Reserve Bank of India (RBI) recently announced two major liquidity measures, a ₹1 trillion…